Semaglutide Significantly Reduces Weight and Boosts Quality of Life in Saudi Patients

Obesity and overweight conditions are growing global health concerns, leading to numerous comorbidities like type 2 diabetes and cardiovascular disease. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated substantial efficacy in weight management and improving metabolic health in various clinical trials worldwide. However, there remains a need for real-world data on its effectiveness and impact on patient well-being in specific regional populations. This single-center study from Saudi Arabia aimed to comprehensively evaluate the effects of Semaglutide on key clinical parameters and health-related quality of life in a local cohort of patients seeking weight loss.

The study revealed significant improvements across multiple clinical and quality of life metrics in patients treated with Semaglutide. Patients experienced an average weight reduction of 10.2 ± 5.1 kg from their baseline, which corresponded to a mean BMI decrease of 3.8 ± 1.9 kg/m² (p<0.001). The most impactful finding was a mean total body weight loss of 10.8% from baseline, underscoring the potent anti-obesity effect of Semaglutide in this real-world setting. Furthermore, metabolic health markers also improved: diabetic patients saw their HbA1c levels decrease by 0.7% (p<0.05), and there was a notable reduction in systolic blood pressure by 5.5 mmHg (p<0.01). Crucially, health-related quality of life scores showed significant positive changes across various domains (p<0.001), indicating enhanced physical function, mental well-being, and overall life satisfaction.